DHA Supplementation of Breastfeeding Mothers Results in Enhanced Motor Skills of Children

Apr 30, 2001, 01:00 ET from Martek Biosciences Corporation

    COLUMBIA, Md., April 30 /PRNewswire/ -- Martek Biosciences Corporation
 (Nasdaq:   MATK) today announced the presentation of clinical findings
 demonstrating the importance of docosahexaenoic acid (DHA) in optimal
 psychomotor development of infants.  DHA is an essential fatty acid naturally
 present in breast milk, and a key building block of the developing infant's
 brain and visual system.  The study, presented at the Pediatric Academic
 Societies' 2001 Annual Meeting in Baltimore, Maryland, showed that breast-fed
 infants whose mothers took dietary supplements of a vegetarian source of DHA
 scored significantly higher on psychomotor development tests than infants
 whose mothers breast-fed but did not supplement with DHA.
     In the study, conducted by researchers at Baylor College of Medicine in
 Houston, TX, breastfeeding mothers received either dietary supplements of DHA
 or a placebo.  The breastfed babies were assessed using the Bayley Psychomotor
 Development Index (PDI).  The results showed that though mothers were
 supplemented for only four months, the psychomotor advantage exhibited by
 babies receiving supplemented breast milk was demonstrated at two and a half
 years of age.
     "These results are the most recent in a series of studies that demonstrate
 the importance of DHA in the mental and motor development of infants and
 children," commented Henry Linsert, Jr., Chairman and CEO of Martek
 Biosciences Corporation.  "I am pleased that the study using Martek's DHA had
 these positive results.  Martek supports breast feeding as the preferred
 method of infant feeding and offers Neuromins(R) as a pure vegetable source of
 DHA to increase levels already present in mothers' milk.  The Company also
 provides a specialized combination of DHA and arachidonic acid (AA), another
 key fatty acid, for supplementation of infant formulas in over 60 countries
 outside the U.S."
 
     Martek Biosciences Corporation develops, manufactures and sells products
 from microalgae.  The Company's products include: (1) specialty, nutritional
 oils for infant formula, nutritional supplements and food ingredients that may
 play a beneficial role in promoting mental and cardiovascular health, and in
 the development of the eyes and central nervous system in newborns; (2) high
 value reagents and technologies to visualize molecular interactions for drug
 discovery and development and; (3) new, powerful fluorescent markers for
 diagnostics, rapid miniaturized screening, and gene and protein detection.
 
     This press release contains forward-looking statements regarding potential
 benefits of Martek's oils. Such statements involve risks and uncertainties
 that could cause future actual results to differ due to a variety of risk
 factors, including without limitation those factors set forth in Exhibit 99.1
 to the Company's Form 10-Q for the fiscal quarter ended January 31, 2001 and
 from time to time in the Company's filings with the Securities and Exchange
 Commission.
 
     CONTACT:  Angela Tsetsis, Director of Marketing and Sales of Martek
 Biosciences Corporation, 410-740-0081.
 
 

SOURCE Martek Biosciences Corporation
    COLUMBIA, Md., April 30 /PRNewswire/ -- Martek Biosciences Corporation
 (Nasdaq:   MATK) today announced the presentation of clinical findings
 demonstrating the importance of docosahexaenoic acid (DHA) in optimal
 psychomotor development of infants.  DHA is an essential fatty acid naturally
 present in breast milk, and a key building block of the developing infant's
 brain and visual system.  The study, presented at the Pediatric Academic
 Societies' 2001 Annual Meeting in Baltimore, Maryland, showed that breast-fed
 infants whose mothers took dietary supplements of a vegetarian source of DHA
 scored significantly higher on psychomotor development tests than infants
 whose mothers breast-fed but did not supplement with DHA.
     In the study, conducted by researchers at Baylor College of Medicine in
 Houston, TX, breastfeeding mothers received either dietary supplements of DHA
 or a placebo.  The breastfed babies were assessed using the Bayley Psychomotor
 Development Index (PDI).  The results showed that though mothers were
 supplemented for only four months, the psychomotor advantage exhibited by
 babies receiving supplemented breast milk was demonstrated at two and a half
 years of age.
     "These results are the most recent in a series of studies that demonstrate
 the importance of DHA in the mental and motor development of infants and
 children," commented Henry Linsert, Jr., Chairman and CEO of Martek
 Biosciences Corporation.  "I am pleased that the study using Martek's DHA had
 these positive results.  Martek supports breast feeding as the preferred
 method of infant feeding and offers Neuromins(R) as a pure vegetable source of
 DHA to increase levels already present in mothers' milk.  The Company also
 provides a specialized combination of DHA and arachidonic acid (AA), another
 key fatty acid, for supplementation of infant formulas in over 60 countries
 outside the U.S."
 
     Martek Biosciences Corporation develops, manufactures and sells products
 from microalgae.  The Company's products include: (1) specialty, nutritional
 oils for infant formula, nutritional supplements and food ingredients that may
 play a beneficial role in promoting mental and cardiovascular health, and in
 the development of the eyes and central nervous system in newborns; (2) high
 value reagents and technologies to visualize molecular interactions for drug
 discovery and development and; (3) new, powerful fluorescent markers for
 diagnostics, rapid miniaturized screening, and gene and protein detection.
 
     This press release contains forward-looking statements regarding potential
 benefits of Martek's oils. Such statements involve risks and uncertainties
 that could cause future actual results to differ due to a variety of risk
 factors, including without limitation those factors set forth in Exhibit 99.1
 to the Company's Form 10-Q for the fiscal quarter ended January 31, 2001 and
 from time to time in the Company's filings with the Securities and Exchange
 Commission.
 
     CONTACT:  Angela Tsetsis, Director of Marketing and Sales of Martek
 Biosciences Corporation, 410-740-0081.
 
 SOURCE  Martek Biosciences Corporation